All articles tagged with #ad109
A new oral medication called AD109 shows promise in treating sleep apnea, potentially offering a more comfortable alternative to CPAP machines, with positive Phase 3 trial results indicating it could be approved by the FDA in 2026, though full data on side effects and efficacy in chronic conditions are pending.
Researchers are conducting a third clinical trial for AD109, a drug that could potentially replace CPAP machines for people with mild obstructive sleep apnea. Developed by Apnimed, AD109 combines aroxybutynin and atomoxetine, and has shown promising results in improving sleep apnea symptoms. With 39 million Americans affected by sleep apnea, this drug could offer a more convenient treatment option.